Hanan Hagar
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Suez Canal University (2024); West Virginia University (2020); California Institute of Technology (1977); Jet Propulsion Laboratory (1979); Zagazig University (1997–2026); King Saud University (2002–2025); West Virginia University Hospitals (2020); King Khalid University Hospital (2002–2023); King Khalid University (2014–2019)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Hanan Hagar's research investigates the protective effects of various compounds against experimentally induced diseases and toxicities in animal models, primarily rats. Her work often focuses on mitigating damage to organs such as the liver, kidneys, heart, and pancreas by exploring the underlying mechanisms of disease and the potential of therapeutic agents. She has published studies examining how pyridoxamine can attenuate liver fibrosis by combating oxidative stress and balancing matrix metalloproteinases, and how carvacrol exhibits protective properties against gastric ulcers through antioxidant, anti-inflammatory, and antiapoptotic mechanisms.
Further investigations by Hagar include the role of cyanocobalamin and/or calcitriol in mitigating tamoxifen-induced renal damage, and the protective effect of rutin trihydrate against cisplatin-induced cardiac toxicity. She has also explored the use of chitosan nanoparticles for liver injury and the inhibition of sepsis-induced pancreatic injury by leukotriene receptor antagonism. Her recent systematic reviews and meta-analyses address the association between Type 1 Diabetes Mellitus and eating disorders, and the risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors.
Hagar's scholarship metrics include an h-index of 23, with 52 total publications and 1,628 total citations. She is recently active, with her most recent publication in 2026.
Metrics
- h-index: 23
- Publications: 52
- Citations: 1,643
Selected Publications
-
Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs (2026)
-
The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis (2024)
-
Tyrosine phosphorylation in DNA damage and cell death in hypoxic injury to LLC-PK1 cells (1997)
-
Role of reactive oxygen metabolites in DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells (1996)
-
Endonuclease induced DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells (1996)
Collaboration Network
Top Collaborators
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- The risk of bone fractures in dementia patients receiving acetylcholinesterase inhibitors: a meta-analysis
- Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs
- Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs
- Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs
- Dual-mechanism of phytochemicals in cancer therapy: synergistic anti-angiogenic potency in cancer and proangiogenic impact against chemotherapy-induced cytotoxicity in vital organs
Similar Researchers
Based on overlapping research topics